TORONTO and BOSTON, Aug. 23,
2017 /PRNewswire/ -- Bionik Laboratories Corp. (OTCQB:BNKL)
("Bionik" or the "Company"), a robotics company focused on
providing rehabilitation and assistive technology solutions to
individuals with neurological and mobility challenges from hospital
to home, today reported that it has been featured in numerous high
profile media publications – including Fortune and The
Verge – following the Company's announcement of its integration
of Amazon Echo into its ARKE™ lower body exoskeletons earlier this
month.
The Company's announcement that its lower body exoskeletons will
now utilize Amazon's Echo ("Echo") technology and Alexa Voice Service ("Alexa") drew interest from
prominent business and technology publications as a first-to-market
innovation.
The article in Fortune features Bionik's ARKE lower body
exoskeleton as a technology that could help injured people be more
mobile within their own homes, enabling people with spinal cord or
other injuries to walk and perform other physical functions they
might not otherwise be able to. It also highlights the success of
Bionik's assistive robotics for stroke rehabilitation within the
clinical setting.
Bionik was also featured in an article by The
Verge, which highlights the innovation behind the
Company's technology and the integration of Echo and Alexa into its
ARKE lower body exoskeletons. The piece discusses how ARKE can be
controlled via an app on a tablet or by reacting automatically to
users' movements through sensors that detect when the wearer shifts
their weight. Now with Echo and Alexa, the ARKE has an enhanced
level of control for the user.
"It is a terrific achievement for our company to be featured in
premier publications such as Fortune and The Verge, as well as a
timely one, as the medical robotics market has begun to garner more
attention worldwide," said Peter
Bloch, Chief Executive Officer and Chairman of the Board of
Bionik Laboratories. "We see great potential for our technology to
help alleviate mobility issues for people around the world, and
this exposure will help educate the market about our capabilities.
We are excited for all of the opportunities ahead of us, and look
forward to seeing the difference our technology can make."
Other prominent news outlets that featured the Company's
technology announcement include USA Today,
Engadget, ZDNet, and
Geekwire.
The ARKE™ exoskeleton utilizes Bionik's proprietary transmission
and actuation system, making it one of the most powerful robotic
devices compared to similar systems. It will now include device
control, utilizing multiple sensors located throughout the device
in combination with Alexa. Users will be able to activate different
activity modes, such as Standing and Walking, by saying "Alexa, I'm
ready to stand" or "Alexa, I'm ready to walk."
About Bionik Laboratories
Bionik Laboratories (OTCQB:BNKL) is a robotics company focused
on providing rehabilitation and mobility solutions to individuals
with neurological and mobility challenges from hospital to home.
The Company has a portfolio of products focused on upper and lower
extremity rehabilitation for stroke and other mobility-impaired
patients, including three products on the market and four products
in varying stages of development. The InMotion Systems — the
InMotion ARM™, InMotion Wrist™, InMotion Hand™ and InMotion
AnkleBot™ — are designed to provide intelligent, patient-adaptive
therapy in a manner that has been clinically verified to maximize
neuro-recovery. Bionik is also developing a lower-body exoskeleton,
ARKE™, designed to allow paraplegics as well as other wheelchair
users the ability to rehabilitate through walking. ARKE is designed
to continually adapt to a patient's ability and provide real-time
feedback to the physiotherapist.
For more information, please
visit www.bioniklabs.com and connect with us
on Twitter, LinkedIn, and Facebook. If you're a
shareholder and wish to receive email alerts for Company news,
please sign up here.
Forward-Looking Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. Forward-looking statements, which involve assumptions
and describe our future plans, strategies, and expectations, are
generally identifiable by use of the words "may," "should,"
"would," "will," "could," "scheduled," "expect," "anticipate,"
"estimate," "believe," "intend," "seek," or "project" or the
negative of these words or other variations on these words or
comparable terminology. Forward-looking statements may include,
without limitation, statements regarding (i) the plans and
objectives of management for future operations, including plans or
objectives relating to the design, development and
commercialization of human exoskeletons and other robotic
rehabilitation products, (ii) a projection of income (including
income/loss), earnings (including earnings/loss) per share, capital
expenditures, dividends, capital structure or other financial
items, (iii) the Company's future financial performance, (iv) the
market and projected market for our existing and planned products
and (v) the assumptions underlying or relating to any statement
described in points (i), (ii), (iii) or (iv) above. Such
forward-looking statements are not meant to predict or guarantee
actual results, performance, events or circumstances, and may not
be realized because they are based upon the Company's current
projections, plans, objectives, beliefs, expectations, estimates
and assumptions, and are subject to a number of risks and
uncertainties and other influences, many of which the Company has
no control. Actual results and the timing of certain events and
circumstances may differ materially from those described by the
forward-looking statements as a result of these risks and
uncertainties. Factors that may influence or contribute to the
inaccuracy of the forward-looking statements or cause actual
results to differ materially from expected or desired results may
include, without limitation, the Company's inability to obtain
additional financing, the significant length of time and resources
associated with the development of our products and related
insufficient cash flows and resulting illiquidity, the Company's
inability to expand the Company's business, significant government
regulation of medical devices and the healthcare industry, lack of
product diversification, volatility in the price of the Company's
raw materials, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. The Company does not undertake to update these
forward-looking statements.
View original
content:http://www.prnewswire.com/news-releases/bionik-laboratories-corp-featured-in-fortune-and-the-verge-for-integration-of-amazon-echo-into-arke-exoskeletons-300507617.html
SOURCE Bionik Laboratories Corp.